Economic value of mitigating Actinobacillus pleuropneumoniae infections in pig fattening herds

Stygar, Anna H.; Niemi, Jarkko; Oliviero, Claudio; Laurila, Tapio; Heinonen, Mari

doi:10.1016/j.agsy.2016.02.005

Cited by 23 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meticulous daily clinical inspections are necessary to detect early signs of disease and to facilitate timely interventions. Comparing cleaning, vaccination and medication strategies (and combinations thereof) for mitigation of pleuropneumonia, it was found that the choice of protocol with regard to economic value depended on prevalence and severity of disease as well as efficiency of the protocol used (Stygar, Niemi, Oliviero, Laurila, & Heinonen, ). In peracute disease, pigs often die without showing any typical clinical signs (Gottschalk, ).…”

Section: Prevention Control and Treatmentmentioning

confidence: 99%

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Sassu

Bossé

Tobias

et al. 2017

Transbound Emerg Dis

145

178

View full text Add to dashboard Cite

Summary Porcine pleuropneumonia, caused by the bacterial porcine respiratory tract pathogen Actinobacillus pleuropneumoniae, leads to high economic losses in affected swine herds in most countries of the world. Pigs affected by peracute and acute disease suffer from severe respiratory distress with high lethality. The agent was first described in 1957 and, since then, knowledge about the pathogen itself, and its interactions with the host, has increased continuously. This is, in part, due to the fact that experimental infections can be studied in the natural host. However, the fact that most commercial pigs are colonized by this pathogen has hampered the applicability of knowledge gained under experimental conditions. In addition, several factors are involved in development of disease, and these have often been studied individually. In a DISCONTOOLS initiative, members from science, industry and clinics exchanged their expertise and empirical observations and identified the major gaps in knowledge. This review sums up published results and expert opinions, within the fields of pathogenesis, epidemiology, transmission, immune response to infection, as well as the main means of prevention, detection and control. The gaps that still remain to be filled are highlighted, and present as well as future challenges in the control of this disease are addressed.

show abstract

Section: Prevention Control and Treatmentmentioning

confidence: 99%

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Sassu

Bossé

Tobias

et al. 2017

Transbound Emerg Dis

145

178

View full text Add to dashboard Cite

show abstract

“…However, it appears that the examples given would not fulfill this condition, as there are well-known herd-health control measures. 93,94,95,96,97 The pathogens mentioned are often naturally present in swine and may cause disease following stress (e.g. due to other infections, housing and climate problems, bad management).…”

Section: Measurement Of Antimicrobial Susceptibilitymentioning

confidence: 99%

EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA)

Murphy¹,

Ricci²,

Auce³

et al. 2017

EFS2

146

104

View full text Add to dashboard Cite

EFSA and EMA have jointly reviewed measures taken in the EU to reduce the need for and use of antimicrobials in food-producing animals, and the resultant impacts on antimicrobial resistance (AMR). Reduction strategies have been implemented successfully in some Member States. Such strategies include national reduction targets, benchmarking of antimicrobial use, controls on prescribing and restrictions on use of specific critically important antimicrobials, together with improvements to animal husbandry and disease prevention and control measures. Due to the multiplicity of factors contributing to AMR, the impact of any single measure is difficult to quantify, although there is evidence of an association between reduction in antimicrobial use and reduced AMR. To minimise antimicrobial use, a multifaceted integrated approach should be implemented, adapted to local circumstances. Recommended options (non-prioritised) include: development of national strategies; harmonised systems for monitoring antimicrobial use and AMR development; establishing national targets for antimicrobial use reduction; use of on-farm health plans; increasing the responsibility of veterinarians for antimicrobial prescribing; training, education and raising public awareness; increasing the availability of rapid and reliable diagnostics; improving husbandry and management procedures for disease prevention and control; rethinking livestock production systems to reduce inherent disease risk. A limited number of studies provide robust evidence of alternatives to antimicrobials that positively influence health parameters. Possible alternatives include probiotics and prebiotics, competitive exclusion, bacteriophages, immunomodulators, organic acids and teat sealants. Development of a legislative framework that permits the use of specific products as alternatives should be considered. Further research to evaluate the potential of alternative farming systems on reducing AMR is also recommended. Animals suffering from bacterial infections should only be treated with antimicrobials based on veterinary diagnosis and prescription. Options should be reviewed to phase EFSA Journal 2017;15(1):4666 www.efsa.europa.eu/efsajournal out most preventive use of antimicrobials and to reduce and refine metaphylaxis by applying recognised alternative measures.

show abstract

“…Conversely, the increased risk of disease incursion will force farmers to invest in preventive measures and subsequently decrease producer incentives to invest in new production. Over time, this can result in reduced livestock production and a probable increase in producer prices as the cost of elevated disease risk must be covered, further lowering incentives for adopting good animal health practices on-farm (26,27,28).…”

Section: Implications Of Impacts -What Does a New Disease Mean For Stmentioning

confidence: 99%

The economic impact of a new animal disease: same effects in developed and developing countries?

Rich¹,

Niemi²

2017

Rev. Sci. Tech. OIE

View full text Add to dashboard Cite

Animal disease outbreaks generate a range of economic and non-economic impacts. While a significant number of research studies have estimated the effects of various diseases in a variety of contexts, examining the differential impacts and implications associated with the introduction of a novel disease into a developing country, as opposed to a developed one, is a rich area for further research. In this paper, the authors highlight some of the key dimensions and implications associated with the impacts of new diseases, how they differ in different contexts, and their implications for public policy.

show abstract

Economic value of mitigating Actinobacillus pleuropneumoniae infections in pig fattening herds

Cited by 23 publications

References 21 publications

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA)

The economic impact of a new animal disease: same effects in developed and developing countries?

Contact Info

Product

Resources

About